I expect the KEAPSAKE PH2 data to be good, which should take the stock to 12+ sp in coming months. Data is expected this Q. They have decent amount of cash to fund their trials into late 2H, 2022.
With upcoming T1D data due "early Q4, 2021", we could see share price spike to between 2.50 -3.50 before fading back down to low 2s before starting the climb back up for the further catalyst due 2022
With a huge upcoming catalyst - CAPLYTA PDUFA due December 17th, 2021, it will make or break this stock - with an approval from the FDA, I expect pt of around 57, with possibility to hit all-time high within a year from CAPLYTA launch. There is however always a possibility of CRL from the FDA, if that is the case, expect mid 20s - low 30s before recovering.
Good tutes (Ra and Redmill) loaded recently - Has catalyst coming up this month and 2H, 2020 - My current avg is 4.77, planning on holding until the end of this year.
Play is based on positive news or not in Mid 2020, if positive PH3, we will see explosive move again to as high as 40 - 60 but if negative, we can see ~15s --- It is good longer term stock since they do have a drug approved already and have plenty of cash on hand to hget the drug to the market - 240 sales reps and had $224 million in cash and equ. In my opinion,...
I have been following this on volume after the offering and have liked it so far. Decent channel + they have approved drug which is/was scheduled to hit the market in 2Q but might be pushed back much further due to the coronavirus.
